title: Inhalation of nebulized nitroglycerin in dogs with experimental pulmonary hypertension induced by U46619.
abstract: BACKGROUND
  Pulmonary hypertension (PH) causes mortality in some congenital and acquired heart and lung diseases. However, inhalation of NO gas requires complicated and expensive instruments and elaborate preparations to avoid toxic gas administration. We tested the effectiveness and safety of inhaled nebulized nitroglycerin (Neb-NTG) in dogs with experimental PH.
  
  
  METHODS
  Experimental PH was induced by continuous infusion of a thromboxane analog (U46619). The U46619 infusion rate was adjusted to maintain a systolic pulmonary artery pressure (PAP) at 40 mmHg in 10 anesthetized and mechanically ventilated dogs. Then, 20 micrograms/kg of NTG liquid nebulized by compressed air was inhaled.
  
  
  RESULTS
  After infusion of U46619, the systolic, diastolic and mean PAP increased by 119%, 228% and 169%, respectively, and the systolic, diastolic and mean systemic arterial pressures (SAP) increased by 19%, 29% and 23%, respectively. The systolic pulmonary to systemic pressure ratio (Pp/Ps) and mean Pp/Ps increased by 83% and 113%, respectively, and the pulmonary vascular resistance (PVR), systemic vascular resistance (SVR) and pulmonary to systemic resistance ratio (Rp/Rs) increased by 341%, 100% and 145%, respectively. After inhalation of Neb-NTG in dogs with experimental PH, systolic, diastolic and mean PAP and PVR decreased by 25 +/- 4, 26 +/- 11, 25 +/- 9 and 31 +/- 21%, respectively. There were no significant changes in systolic, diastolic and mean SAP, SVR, cardiac output and plasma methemoglobin concentrations. The systolic and mean Pp/Ps decreased by 18 +/- 7 and 20 +/- 7%, respectively. The Rp/Rs decreased by 25 +/- 13%.
  
  
  CONCLUSIONS
  The results of this study demonstrate that Neb-NTG is an effective and selective pulmonary vasodilator and may offer a new therapeutic option for PH.
authors.affiliation: Department of Pediatrics, Jichi Medical School, Tochigi, Japan.
authors.forename: F
authors.initials: F
authors.lastname: Gong
authors.forename: H
authors.initials: H
authors.lastname: Shiraishi
authors.forename: Y
authors.initials: Y
authors.lastname: Kikuchi
authors.forename: M
authors.initials: M
authors.lastname: Hoshina
authors.forename: K
authors.initials: K
authors.lastname: Ichihashi
authors.forename: Y
authors.initials: Y
authors.lastname: Sato
authors.forename: M Y
authors.initials: MY
authors.lastname: Momoi
mesh_terms: D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; D000280:Administration, Inhalation; D000818:Animals; D004285:Dogs; D006439:Hemodynamics; D006976:Hypertension, Pulmonary / Q000139:chemically induced / Q000188:drug therapy* / Q000401:mortality; D009330:Nebulizers and Vaporizers; D005996:Nitroglycerin / Q000008:administration & dosage* / Q000627:therapeutic use; D014655:Vascular Resistance; D014665:Vasodilator Agents / Q000008:administration & dosage* / Q000627:therapeutic use
chemical_list: D014665:Vasodilator Agents; D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; D005996:Nitroglycerin